The research, led by Minglu Li and colleagues at the Department of Hematology of Aerospace Center Hospital in Beijing, set out to build what statisticians call a nomogram — a visual scoring instrument that converts a handful of patient characteristics into a personalized probability estimate. What makes this nomogram distinctive is its statistical engine: rather than treating death from any cause as a single uniform outcome, the team used a competing-risk framework that explicitly accounts for the fact that a patient who relapses and dies of leukemia is no longer at risk of dying from transplant complications. In survival analysis, ignoring such competing events can badly distort risk estimates, inflating apparent mortality rates and muddying clinical decision-making. The Fine-Gray model, the framework the researchers adopted, was developed precisely to handle this subtlety, modeling the cumulative incidence of the event of interest while treating relapse as the competing event.

The study population consisted of 587 patients with high-risk or refractory acute leukemia who underwent their first allogeneic transplant between January 2015 and December 2021 at the single center. To test the model honestly, the team randomly split the cohort into a training set of 411 patients, used to build the model, and a validation set of 176 patients, held back to see how the model performed on data it had never seen. This kind of internal validation is a critical safeguard against overfitting — the statistical sin of building a model that memorizes the quirks of one dataset rather than capturing genuine biological patterns that generalize to new patients.

Selecting which variables to include was itself a methodical process. The researchers turned to least absolute shrinkage and selection operator regression, better known as LASSO, a technique that shrinks the coefficients of weak predictors toward zero and effectively eliminates them, leaving behind only the most informative variables. To ensure the selection was stable rather than a fluke of the particular data, they employed ten-fold cross-validation, repeatedly partitioning the training data so that the variable selection process was tested across many different subsets. Out of this rigorous filtering emerged six predictors of non-relapse mortality: patient age, disease status before transplantation (whether the leukemia was in complete remission or not), the Hematopoietic Cell Transplantation-specific Comorbidity Index score, the time to white blood cell engraftment, the time to platelet engraftment, and the grade of acute graft-versus-host disease.

Each of these predictors tells a clinically meaningful story. Age and comorbidities reflect the body’s baseline resilience going into the procedure — an older patient with significant organ dysfunction simply has less physiological reserve to withstand the assault of conditioning chemotherapy, immune suppression, and potential infections. Pre-transplant disease status matters because patients transplanted in complete remission generally fare better than those transplanted with active, refractory disease. The engraftment timings are particularly interesting because they are early post-transplant events: if the donor’s stem cells take longer than 21 days to produce white blood cells, or longer than 14 days to produce platelets, that sluggish recovery signals a fragile marrow environment associated with higher risk. And acute graft-versus-host disease — the notorious complication in which donor immune cells attack the recipient’s tissues — remains one of the most feared drivers of transplant-related death, so its grade from II to IV carries substantial weight in the model.

The performance numbers are where the tool earns its keep. In the training cohort, the time-dependent area under the receiver operating characteristic curve — a standard measure of how well a model separates those who experience the event from those who do not — reached 0.786 at one year, 0.764 at two years, and 0.746 at three years. In the validation cohort, the model actually performed slightly better, with AUCs of 0.818, 0.799, and 0.806 at the same time points. Values in this range indicate useful, though not perfect, discrimination. The concordance index, a related measure of predictive accuracy for survival data, came in at 0.715 after bootstrap correction in the training set and 0.767 in the validation set, where the 95 percent confidence interval spanned 0.703 to 0.831.

Discrimination alone is not enough, however; a model must also be calibrated, meaning its predicted probabilities should match observed reality. A model that tells every patient they have a 30 percent risk when only 10 percent actually die is discriminating poorly or calibrating poorly, and clinicians acting on such numbers could make harmful decisions. The team assessed calibration using optimism-corrected calibration slopes derived from 200 bootstrap resamples, obtaining values of 0.94, 0.92, and 0.97 at one, two, and three years in the training cohort — figures close to the ideal value of 1.0. In the validation cohort, the slopes of 1.30, 1.14, and 1.16 suggested the model was, if anything, slightly conservative in that patient group, a direction of error that is generally less dangerous than overconfidence.

Perhaps the most practically important result came from the head-to-head comparison with the HCT-CI, the comorbidity index that has long served as a standard pre-transplant risk assessment tool. The new nomogram significantly outperformed it, with a C-index difference of 0.114 (P = 0.020) in the training cohort and 0.191 (P = 0.008) in the validation cohort. The advantage makes intuitive sense: the HCT-CI captures only the patient’s condition before the transplant, whereas the nomogram folds in early post-transplant events like engraftment speed and graft-versus-host disease, which carry fresh, dynamic information about how the transplant is actually unfolding. Decision curve analysis reinforced the point, showing that across clinically relevant threshold probabilities from 5 to 50 percent, the nomogram delivered positive net benefit and consistently beat both the treat-all and treat-none default strategies — meaning that clinicians using the tool to guide decisions would, on average, make better calls than following blanket policies.

The study’s limitations are worth keeping in view. It was a single-center, retrospective analysis, and all 587 patients were treated at one institution in Beijing, so the model’s generalizability to other populations, donor types, and conditioning regimens remains to be demonstrated. External validation on independent cohorts at different centers is the natural next step, and the authors themselves frame the tool as internally validated rather than externally proven. Still, the work represents a meaningful advance in a field where risk prediction has often relied on static, pre-transplant snapshots. By integrating baseline characteristics with the early dynamics of recovery, the nomogram gives clinicians a living risk estimate that can be computed in the crucial weeks after transplantation — precisely the window when interventions such as intensified monitoring, prophylactic treatments, or early escalation of care might tip the balance for the patients who need it most. For the growing population of high-risk and refractory leukemia patients whose only curative option is an allogeneic transplant, turning the black box of non-relapse mortality into a quantifiable, actionable number could ultimately mean the difference between anticipation and reaction.

Subject of Research: A competing-risk nomogram for predicting non-relapse mortality after allogeneic hematopoietic stem cell transplantation in high-risk or refractory acute leukemia

Article Title: Development and internal validation of a competing-risk nomogram for predicting non-relapse mortality after allogeneic hematopoietic stem cell transplantation in patients with high-risk or refractory acute leukemia

Article References: Li, M., Zhang, W., Zhang, S., Fei, X., Zhao, J., Luo, R., & Wang, J. (2026). Development and internal validation of a competing-risk nomogram for predicting non-relapse mortality after allogeneic hematopoietic stem cell transplantation in patients with high-risk or refractory acute leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-026-07294-5

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07294-5

Keywords: non-relapse mortality, allogeneic hematopoietic stem cell transplantation, acute leukemia, nomogram, competing-risk model, Fine-Gray model, LASSO regression, HCT-CI, graft-versus-host disease, engraftment, risk prediction, hematology

The research, published in Annals of Hematology by a team led by Jiayuan Guo, Liuqing Huang, Zixuan Li, and senior authors Liping Dou, Zhenyang Gu, and Chunji Gao, examined 106 consecutive patients who underwent allogeneic hematopoietic stem cell transplantation at a single institution between January 2010 and January 2025. Of these, 71 had T-cell acute lymphoblastic leukemia and 35 had T-cell lymphoblastic lymphoma. Allogeneic transplantation, in which a patient receives blood-forming stem cells from a genetically matched donor, remains one of the most intensive therapies in medicine, replacing a patient’s entire immune and hematopoietic system with that of another person. It is typically reserved for patients with high-risk or relapsed disease, making the question of which diagnosis benefits most from the procedure clinically urgent.

The headline finding is one of equivalence. The researchers detected no statistically significant differences between the two groups in overall survival, disease-free survival, or graft-versus-host disease-free, relapse-free survival, a composite measure that captures the three main threats facing transplant recipients: death, relapse, and chronic immune complications. Nor did the cumulative incidence of relapse or the cumulative incidence of non-relapse mortality, which counts deaths from transplant-related causes such as infection and organ damage rather than from returning cancer, differ meaningfully between the leukemia and lymphoma cohorts. In multivariable analyses that adjusted for other clinical variables, the diagnosis itself was not associated with any of these outcomes.

That overall equivalence, however, conceals a more nuanced temporal story. Using time-dependent statistical models, the team found that the effect of diagnosis on survival changed over the course of follow-up. At six months after transplantation, patients with T-cell lymphoblastic lymphoma had worse overall survival than those with leukemia, with a time-specific hazard ratio of 2.41 and a 95 percent confidence interval of 1.10 to 5.28, a statistically significant difference. This early vulnerability likely reflects the particular hazards of the immediate post-transplant period, when conditioning regimens, infections, and acute immune reactions claim the greatest toll.

By 36 months, the picture had reversed. At that later time point, T-cell lymphoblastic lymphoma was associated with a lower risk of disease-free survival failure, with a hazard ratio of 0.16, and a dramatically lower risk of non-relapse mortality, with a subdistribution hazard ratio of just 0.06. In other words, lymphoma patients who survived the critical first months appeared to enjoy a safer long-term course than their leukemia counterparts. Consistent with this, the restricted mean survival time analysis, which quantifies average survival over a fixed window, showed that the 36-month restricted mean survival time for overall survival was 5.79 months shorter in the lymphoma group, a statistically significant gap, while disease-free and graft-versus-host disease-free, relapse-free survival showed no significant differences by this measure.

The researchers also observed that moderate to severe chronic graft-versus-host disease, a debilitating condition in which donor immune cells attack the recipient’s healthy tissues, was less frequent among patients with T-cell lymphoblastic lymphoma. This difference persisted in propensity score-matched cohorts, a technique that pairs patients from the two groups with similar baseline characteristics to reduce the confounding that plagues observational comparisons. Most other outcomes, however, remained indistinguishable between the matched groups, reinforcing the central conclusion that diagnosis alone does not determine transplant success.

The study’s robustness was tested in several ways. Complete case analyses focusing on white blood cell count and lactic dehydrogenase, two markers of disease burden that are often elevated in aggressive lymphoid malignancies, did not materially change the estimates. Nor did analyses restricted to patients in complete remission with evaluable measurable residual disease, the sensitive molecular test that detects tiny quantities of malignant cells below the threshold of microscopic examination. These sensitivity analyses suggest that the equivalence finding is not an artifact of missing data or of comparing patients at different disease stages.

The scientific backdrop to this work is a quiet revolution in how these two diseases are understood. Historically unified as a single entity, T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma have been increasingly distinguished by molecular diagnostics and cytogenetic testing, which have revealed inherent differences in their genetic signatures and chromosomal profiles. Yet comparative outcome data following allogeneic transplantation had remained scarce, leaving transplant physicians without a firm evidence base for counseling patients from the two diagnostic groups. This study, spanning fifteen years of consecutive transplants, helps fill that gap.

The clinical implications are straightforward. For patients and physicians weighing the risks and benefits of allogeneic transplantation, the diagnosis of leukemia versus lymphoma should not, on its own, drive the decision. Instead, the findings suggest that other factors, such as disease status at transplant, measurable residual disease, donor type, and patient comorbidities, remain the more meaningful predictors of outcome. The early survival disadvantage seen in lymphoma patients may warrant heightened vigilance during the first six months after transplant, while the lower late non-relapse mortality offers some reassurance for long-term survivors.

The authors are careful to frame their conclusions with appropriate caution. As a single-center retrospective study of 106 patients, the analysis lacks the statistical power of a large multicenter trial, and the time-dependent effects observed, while statistically significant, rest on modest numbers of events at each time point. The team explicitly calls for confirmation in larger multicenter studies. Still, the work represents one of the most detailed head-to-head comparisons of these two diagnoses in the transplant setting to date, and it delivers a message that is both scientifically interesting and clinically comforting: once malignant T cells drive a patient to a donor transplant, whether they first declared themselves in the marrow or in the lymph nodes may matter far less than doctors once assumed.

Subject of Research: Comparative post-transplant outcomes of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma

Article Title: Clinical outcomes of T-cell acute lymphoblastic leukemia versus T-cell lymphoblastic lymphoma after allogeneic hematopoietic stem cell transplantation

Article References: Guo, J., Huang, L., Li, Z., Zhang, A., Li, M., Zhang, L., Wang, L., Li, F., Wang, L., Jing, Y., Bo, J., Liu, D., Dou, L., Gu, Z., & Gao, C. (2026). Clinical outcomes of T-cell acute lymphoblastic leukemia versus T-cell lymphoblastic lymphoma after allogeneic hematopoietic stem cell transplantation. Annals of Hematology. https://doi.org/10.1007/s00277-026-07295-4

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07295-4

Keywords: T-cell acute lymphoblastic leukemia, T-cell lymphoblastic lymphoma, allogeneic stem cell transplantation, overall survival, graft-versus-host disease, measurable residual disease, non-relapse mortality, propensity score matching, hematology, restricted mean survival time, relapse, Annals of Hematology

Multiple myeloma is a cancer of plasma cells, the antibody-producing white blood cells that reside in the bone marrow. As malignant plasma cells proliferate, they flood the bloodstream with abnormal proteins called free light chains, which are filtered by the kidneys and can precipitate inside the delicate tubules, causing progressive injury. Renal impairment is one of the most feared complications of the disease, affecting a substantial minority of patients at diagnosis, and it has consistently been identified as a risk factor for poorer outcomes across virtually every treatment modality. The standard of care for eligible myeloma patients includes high-dose melphalan chemotherapy followed by rescue with the patient’s own blood-forming stem cells, a procedure known as autologous hematopoietic cell transplantation. But because melphalan is partially cleared by the kidneys, patients with impaired renal function face a pharmacological dilemma: a full dose may accumulate to toxic levels, while a reduced dose may compromise the anti-cancer effect.

The Brazilian research team set out to address a gap that has persisted in the transplant literature. Most published data on transplantation in myeloma patients with renal impairment come from high-volume centers in Europe and North America, equipped with extensive intensive care capacity and multidisciplinary support. Whether similar outcomes could be achieved in resource-constrained settings, where access to dialysis, critical care beds, and broad-spectrum antimicrobials may be more limited, remained an open question. The study therefore examined outcomes at a public hospital in Brazil, capturing the realities of transplant medicine as it is practiced in much of the world rather than only in its most privileged enclaves.

The researchers defined renal impairment strictly, requiring either a serum creatinine above 2 milligrams per deciliter or a creatinine clearance below 40 milliliters per minute, thresholds that indicate serious compromise of kidney function. The 53 patients enrolled in the analysis had a median age of 59 years, and the cohort was characterized by advanced disease at presentation: 82 percent had Durie-Salmon stage IIIA or IIIB disease, and 63 percent fell into stage III of the International Staging System, the most severe category. Notably, 15 of the patients, amounting to 28 percent of the cohort, were dependent on dialysis at the time of their transplant, meaning their kidneys could no longer sustain them without mechanical blood filtration. The vast majority, 81 percent, received a reduced melphalan dose of 140 milligrams per square meter of body surface area or less, reflecting the common clinical practice of dose adjustment in the setting of renal dysfunction.

The toxicity profile documented in the study underscores how demanding this treatment is for patients with failing kidneys. Fifteen patients, or 29 percent of the cohort, experienced grade 3 or 4 overall toxicity, the most severe categories of adverse effects on standard clinical grading scales. Severe oral mucositis, the painful inflammation and ulceration of the lining of the mouth that follows high-dose chemotherapy, affected 17 percent of patients, while 13 percent suffered grade 3 or 4 diarrhea and a comparable proportion experienced severe nausea. Fourteen patients, 26 percent of the total, required admission to the intensive care unit at some point during their transplant course, a figure that highlights the considerable critical care resources consumed by this population and the fragility of patients whose kidneys cannot buffer the metabolic stresses of conditioning chemotherapy.

Perhaps the most clinically actionable finding concerns which factors predicted severe toxicity. Patients who came to transplant in only a partial response to prior therapy, rather than a very good partial or complete response, were significantly more likely to develop grade 3 or 4 toxicity, with a p-value of 0.024 indicating a statistically robust association. Low serum albumin at the time of transplant, a marker of poor nutritional status and general physiological reserve, was also linked to severe toxicity, as was receiving a melphalan dose above 140 milligrams per square meter. Taken together, these associations suggest a coherent biological picture: patients with more active disease, less nutritional reserve, and higher chemotherapy exposure are precisely those whose bodies are least equipped to withstand the conditioning regimen, and clinicians may be able to identify them in advance.

The survival statistics tell a nuanced story. Non-relapse mortality, the proportion of patients who died from causes other than their cancer, such as infections or organ failure related to the transplant itself, stood at 13 percent at 100 days, with infections being the leading cause of these early deaths. At 24 months after transplantation, 48 percent of patients had not experienced disease progression, and 65 percent were still alive. The authors note that these survival figures were comparable to those reported in prior studies conducted in better-resourced settings, a finding they describe as reassuring for centers operating under similar constraints. In other words, despite the higher complication rates and intensive care utilization, carefully selected patients with renal impairment can still derive meaningful benefit from autologous transplantation even outside the world’s wealthiest medical systems.

The analysis also identified predictors of poorer survival that may guide future patient selection. Dialysis dependence at the time of transplant was significantly associated with worse progression-free survival, with a p-value of 0.035, as were advanced disease stage by the International Staging System, with stage 2 and stage 3 disease each independently linked to shorter progression-free survival. For overall survival, the decisive factor was the comorbidity burden: patients with a higher accumulation of coexisting health conditions died more frequently, with a p-value of 0.015. These findings align with the broader understanding that transplant outcomes reflect not just the cancer itself but the whole patient, and they suggest that in resource-limited settings, where intensive care capacity is finite, prioritizing patients with better organ function, earlier-stage disease, and fewer comorbidities may maximize the benefit derived from each transplant performed.

The study’s conclusions carry practical weight for transplant physicians worldwide. The authors recommend optimizing patient selection for hematopoietic cell transplantation and reducing melphalan doses in patients with renal impairment, strategies that may be particularly warranted where healthcare resources are limited. The finding that full-dose melphalan was associated with increased severe toxicity provides quantitative support for the dose-reduction practices already common in many centers, while the link between deep pre-transplant response and lower toxicity argues for maximizing induction therapy before proceeding to transplant in patients with kidney damage. As novel agents continue to improve myeloma control before transplantation, the population of patients reaching transplant with renal impairment may evolve, but this study provides a valuable benchmark for what can currently be achieved.

Beyond its immediate clinical implications, the research fills an important gap in the global evidence base. Transplant outcomes in low- and middle-income countries are chronically underreported, leaving clinicians in those settings to extrapolate from studies conducted under very different conditions. By documenting both the challenges, including high non-relapse mortality and frequent intensive care utilization, and the achievable successes, with two-year overall survival of 65 percent, the São Paulo team has demonstrated that autologous transplantation remains a viable and defensible option for myeloma patients with renal impairment even where resources are stretched. The study was approved by the local institutional ethics board, all participants provided informed consent, and the work was conducted in accordance with the Declaration of Helsinki, with no external funding supporting the research. For the growing number of myeloma patients worldwide who present with damaged kidneys, the message is one of cautious hope: with careful selection, dose adjustment, and honest counseling about the risks, the transplant pathway remains open.

Subject of Research: Autologous hematopoietic cell transplantation outcomes in multiple myeloma patients with renal impairment

Article Title: Outcomes in patients with multiple myeloma and renal impairment undergoing autologous hematopoietic cell transplantation

Article References: Martins, L., Ribeiro, C., Gasparini, J., Otuyama, L., Mariano, L., Atanazio, M., Seguro, F., Martinez, G., Rocha, V., & Fatobene, G. (2026). Outcomes in patients with multiple myeloma and renal impairment undergoing autologous hematopoietic cell transplantation. Annals of Hematology. https://doi.org/10.1007/s00277-026-07152-4

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07152-4

Keywords: multiple myeloma, renal impairment, autologous transplantation, melphalan, dialysis, non-relapse mortality, progression-free survival, overall survival, toxicity, intensive care, Brazil, hematopoietic stem cells

The study, published in Annals of Hematology by a team of Austrian transplant specialists led by Alexandra Donschachner and Johannes Clausen, analyzed a national cohort of 1,112 adult AML patients who received allogeneic stem cell transplants between 2000 and 2017. Nearly half of the patients were women, the median age at transplantation was 51 years, and 63 percent received grafts from unrelated donors. Crucially, the investigators compared outcomes across three consecutive six-year periods, 2000 to 2005, 2006 to 2011, and 2012 to 2017, using broadly comparable conditioning regimens, supportive care standards, and donor selection criteria throughout. That consistency is what makes the dataset scientifically valuable: when treatment frameworks remain stable, shifts in survival can be attributed with greater confidence to genuine changes in patient characteristics and clinical practice rather than to fluctuations in protocol.

The headline numbers tell a story of incremental progress rather than dramatic breakthrough. Five-year overall survival stood at 38 percent for patients transplanted in the earliest era, rose to 45 percent in the middle period, and then settled at 35 percent in the most recent cohort. Taken together, these figures illustrate a pattern that transplant physicians know well: gains in one domain are often offset by pressures in another. Across the entire cohort, the estimated cumulative incidence of non-relapse mortality, meaning death from causes other than the leukemia itself, was 27 percent, while the relapse rate reached 37 percent. In other words, for roughly one patient in four, the procedure itself or its complications proved fatal, and for more than one in three, the underlying malignancy returned.

One of the most revealing aspects of the analysis lies in how patient characteristics shifted over the two decades. Patients transplanted in later years were older on average, and a higher proportion underwent transplantation while in their first complete remission, the point at which chemotherapy has cleared detectable leukemic cells and the disease is at its most controllable. At the same time, the use of unrelated donors expanded steadily, as did reliance on peripheral blood stem cells rather than bone marrow as the graft source. Each of these trends reflects genuine advances: better HLA typing and donor registries made unrelated transplantation safer and more feasible, while improved remission induction allowed more patients to reach transplant in favorable disease status. Yet an aging and more heavily pretreated population brings its own vulnerabilities, including greater susceptibility to organ toxicity, infections, and graft-versus-host disease.

Perhaps the most clinically striking result concerns the subgroup of patients who arrived at transplantation with active, measurable disease, the hardest-to-treat scenario in AML. In this group, overall survival rose from 15 percent in the earliest era to 28 percent in the most recent, a trend that approached statistical significance despite the modest number of patients involved. Even more compelling, relapse incidence in these patients fluctuated significantly across the three periods, falling from 58 percent to 40 percent and then rising again to 54 percent. The authors report this pattern with a p-value of 0.016, indicating that the variation is unlikely to be explained by chance alone. Transplanting a patient with uncontrolled leukemia is a gamble: the graft-versus-leukemia effect, in which donor immune cells attack residual malignant cells, can be lifesaving, but the disease is also primed to regrow. The fluctuations in relapse rates likely mirror changes in patient selection, conditioning intensity, and the availability of salvage therapies.

Why does the most recent cohort not show uniformly better results than its predecessors? The answer appears to lie in the evolving risk profile of the transplant population. As transplantation became available to older patients and to those with more aggressive or refractory disease biology, the population entering the procedure grew inherently sicker. A 35 percent five-year survival in a cohort that includes more elderly patients and more advanced disease may represent better medicine than a 38 percent survival in a younger, fitter population a decade earlier. This phenomenon, sometimes called the risk-shift paradox, complicates naive comparisons of survival statistics across eras and underscores why formal statistical adjustment for patient characteristics is essential in transplant research.

The technical backbone of allogeneic transplantation deserves attention to fully appreciate these findings. The procedure involves destroying a patient’s diseased bone marrow with high-dose chemotherapy, sometimes combined with radiation, and then infusing hematopoietic stem cells from a donor whose human leukocyte antigens, the molecular fingerprints the immune system uses to distinguish self from foreign, closely match those of the recipient. The donor cells repopulate the marrow and, critically, mount an immunological campaign against any residual leukemia. But the same immune machinery can attack the patient’s own tissues, producing graft-versus-host disease, a potentially devastating complication affecting the skin, liver, and gastrointestinal tract. Balancing the graft-versus-leukemia effect against graft-versus-host disease remains the central immunological tightrope of the field, and every improvement in donor matching, prophylaxis, and supportive care nudges that balance forward.

The national scope of the Austrian dataset gives it particular weight. Rather than aggregating results from a handful of high-volume academic centers, which can inflate outcomes through referral bias, the study captured the real-world performance of an entire country’s transplant program, drawing on the Austrian Stem Cell Transplant Registry and involving centers in Vienna, Graz, Innsbruck, and Linz. Registry-based designs of this kind answer a question that single-center studies cannot: what does this procedure actually deliver across the full spectrum of patients and institutions where it is performed today? The open-access publication also means that the full methodological detail, statistical models, and supplementary analyses are freely available to clinicians and researchers worldwide, an increasingly important standard in hematologic research.

What emerges from the analysis is neither triumph nor failure but something more honest: a portrait of a maturing therapy whose benefits are real but unevenly distributed. For patients in first complete remission, particularly those with favorable risk genetics, transplantation offers a genuine chance of long-term cure. For those with active disease at the time of the procedure, survival has improved, but the majority still face formidable odds. The trajectory over the two decades suggests that progress in this field arrives through the accumulation of small refinements, better donor selection, more sophisticated conditioning, improved antimicrobial strategies, and refined supportive care, rather than through any single transformative intervention.

Looking ahead, the study’s authors and the wider transplant community face a clear agenda. Reducing relapse, the leading cause of treatment failure in this cohort, remains the paramount challenge, and it will likely require integrating novel therapeutics, from targeted agents against specific leukemic mutations to cellular immunotherapies, into the peri-transplant period. Meanwhile, lowering non-relapse mortality through gentler conditioning regimens, better graft-versus-host disease prophylaxis, and improved management of infections could lift survival for the growing population of older patients. The Austrian data provide the essential baseline against which these future innovations must be measured, and they affirm a fundamental truth of modern oncology: in the decades-long effort to make bone marrow transplantation a reliable cure for acute myeloid leukemia, steady, measured progress continues, patient by patient and year by year.

Subject of Research: Long-term survival outcomes of allogeneic stem cell transplantation in adults with acute myeloid leukemia

Article Title: Long-term survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia

Article References: Donschachner, A., Pregartner, G., Lindner, B., Berghold, A., Greinix, H., Rabitsch, W., Bauhofer, A., Nachbaur, D., Mitterbauer, M., Huber-Kraßnitzer, B., Cserna, J., Hetzenauer, G., Sill, H., Neumeister, P., & Clausen, J. (2026). Long-term survival after allogeneic stem cell transplantation in patients with acute myeloid leukemia. Annals of Hematology. https://doi.org/10.1007/s00277-026-07275-8

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07275-8

Keywords: acute myeloid leukemia, allogeneic stem cell transplantation, hematopoietic cell transplantation, overall survival, non-relapse mortality, relapse incidence, graft-versus-host disease, unrelated donors, hematologic cancer, Austrian Stem Cell Transplant Registry, prognosis, first complete remission

Conditioning is the intensive preparatory phase that precedes an allogeneic stem cell transplant, in which a patient receives blood-forming cells from a donor. Its purpose is twofold: to wipe out the patient’s diseased bone marrow and malignant cells, and to suppress the immune system enough that the donor cells can engraft rather than being rejected. For decades, many conditioning protocols incorporated total body irradiation, or TBI, because radiation is an effective tool for eradicating malignant cells throughout the body. But irradiating the entire body comes at a cost, particularly for older patients, who face higher risks of organ damage, secondary cancers, and prolonged recovery. Reduced-intensity conditioning regimens were developed precisely to soften this blow, using lower doses of treatment to make transplantation feasible for patients who could never tolerate a myeloablative approach.

One of the most successful reduced-intensity strategies in current use is the Baltimore regimen, which pairs fludarabine with low-dose total body irradiation and high-dose post-transplant cyclophosphamide to prevent graft-versus-host disease. The post-transplant cyclophosphamide component is the crucial innovation: by administering high doses of cyclophosphamide in the days immediately after the donor cells are infused, clinicians can selectively eliminate the rapidly proliferating donor T cells that would otherwise attack the recipient’s tissues, while sparing the slower-dividing stem cells that must rebuild the patient’s blood and immune systems. This approach has transformed haploidentical transplantation, allowing nearly any patient with a healthy relative to serve as a donor.

The problem, as the Grenoble team points out, is that not every transplant center has reliable access to total body irradiation. Radiation oncology capacity varies widely across countries and institutions, and in some settings the logistical burden of coordinating TBI sessions for transplant patients is prohibitive. To address this gap, the researchers evaluated a modified, radiation-free version of the Baltimore regimen, designated FE2B2, which replaces the irradiation component with a combination of fludarabine, cyclophosphamide, and busulfan. Fludarabine is a purine analog that potently suppresses lymphocytes; cyclophosphamide adds further immunosuppression and cytotoxic activity; and busulfan, an alkylating agent, takes over the marrow-ablative role that low-dose radiation would otherwise play. The regimen retains the signature post-transplant high-dose cyclophosphamide for graft-versus-host disease prophylaxis.

To test whether this modified protocol could stand in for the original, the investigators conducted a non-interventional, monocentric, retrospective cohort study at their tertiary care center. They included adult patients over the age of eighteen who had received an HLA haploidentical or mismatched unrelated donor peripheral blood stem cell graft with the non-TBI modified Baltimore conditioning between March 2016 and April 2022. The primary endpoints were overall survival at two and five years after transplantation. Secondary endpoints covered the full spectrum of transplant outcomes: donor engraftment, progression-free survival, non-relapse mortality, graft-versus-host disease-free and relapse-free survival, and the incidence of acute and chronic graft-versus-host disease at the same time points.

The cohort comprised sixty-five patients, and their profile reflects exactly the population for whom such a regimen is designed. The median age of the recipients was sixty-six years, an age at which conventional ablative conditioning would be considered unacceptably toxic by many centers. One-third of the patients carried a hematopoietic cell transplantation-specific comorbidity index score of three or higher, signaling substantial pre-existing health burdens. Forty-three percent of the transplants came from haploidentical family donors, meaning donors who share only half of the patient’s human leukocyte antigens, while fifty-seven percent came from mismatched unrelated donors. Both donor types carry elevated immunologic risk compared with fully matched donors, making the results particularly relevant to patients who lack a well-matched donor option. The median follow-up reached sixty-one months, long enough to capture genuinely durable outcomes.

The engraftment data were unambiguous. Neutrophil engraftment, the first milestone of transplant success indicating that donor cells have taken hold and are producing infection-fighting white blood cells, was achieved in every single patient. Platelet engraftment, which restores clotting capacity and is typically slower and less reliable, occurred in ninety-seven percent of patients. These figures suggest that the busulfan-based, radiation-free conditioning creates a receptive marrow environment as effectively as the irradiation-based original. Graft-versus-host disease rates were also in line with expectations for this transplant setting: the cumulative incidence of grade II-IV acute graft-versus-host disease was forty-five percent, grade III-IV acute disease was fourteen percent, chronic graft-versus-host disease reached twenty percent at both two and five years, and moderate to severe chronic disease affected twelve percent of patients.

Non-relapse mortality, the measure of deaths caused by the transplant procedure itself rather than by returning cancer, was twenty-two percent at two years and twenty-five percent at five years. The authors note that four patients died within the first twenty days after transplant, three from hemorrhagic complications and one from cardiogenic shock secondary to pericarditis, underlining that early toxicity remains a genuine hazard in this fragile population even under a reduced-intensity approach. Survival outcomes were correspondingly moderate: two-year and five-year overall survival stood at forty-eight percent and thirty-seven percent respectively, progression-free survival at forty-three percent and thirty-two percent, and graft-versus-host disease-free, relapse-free survival, a stringent composite endpoint requiring patients to remain free of both relapse and significant graft-versus-host disease, at twenty-nine percent and nineteen percent.

The authors conclude that in their cohort of elderly and frail patients with high-risk disease, the FE2B2 regimen demonstrated acceptable toxicity, with long-term outcomes that align with published data for the classical Baltimore conditioning that includes total body irradiation. In practical terms, this means that centers without access to radiation facilities can offer a defensible alternative without apparently compromising the fundamental transplant outcomes that matter most to patients. Given that roughly half of patients diagnosed with hematologic malignancies are over sixty and that donor availability increasingly favors haploidentical options, a validated radiation-free pathway could meaningfully expand the number of older patients who are offered curative-intent transplantation rather than palliative treatment alone.

The study’s limitations are those inherent to its design. As a retrospective, single-center analysis of sixty-five patients, it cannot deliver the statistical power of a randomized trial, and center-specific supportive care practices may influence outcomes such as early hemorrhagic deaths. A longer median follow-up beyond five years would also sharpen estimates of late relapse and chronic graft-versus-host disease. Nevertheless, the findings add to a growing body of evidence that transplant eligibility need not be dictated by age or by the technological resources of a given hospital. For elderly and unfit patients with high-risk blood cancers and only half-matched or mismatched donors available, the modified Baltimore regimen offers a chemically engineered route to engraftment that requires no radiation at all, bringing a once-exclusive therapy closer to universal availability.

Subject of Research: A non-TBI chemotherapy conditioning regimen for allogeneic stem cell transplantation in elderly or unfit patients with haploidentical or mismatched unrelated donors.

Article Title: A Baltimore-modified non-TBI conditioning for allogeneic stem cell transplantation in elderly or unfit patients with haploidentical or mismatched donors

Article References: Volpari, V., Bulabois, C.-E., Thiebaut-Bertrand, A., Regny, C., Park, S., Carre, M., & Meunier, M. (2026). A Baltimore-modified non-TBI conditioning for allogeneic stem cell transplantation in elderly or unfit patients with haploidentical or mismatched donors. Annals of Hematology. https://doi.org/10.1007/s00277-026-07260-1

Image Credits: AI Generated

DOI: 10.1007/s00277-026-07260-1

Keywords: allogeneic stem cell transplantation, reduced-intensity conditioning, Baltimore regimen, total body irradiation, haploidentical donor, mismatched unrelated donor, post-transplant cyclophosphamide, graft-versus-host disease, non-relapse mortality, elderly patients, busulfan, hematologic malignancies